|1.||Aldrich, Melissa B: 1 article (05/2012)|
|2.||Robinson, Holly: 1 article (05/2012)|
|3.||Hall, Mary A: 1 article (05/2012)|
|4.||Lachance, Pier-Anne: 1 article (05/2012)|
|5.||Sevick-Muraca, Eva M: 1 article (05/2012)|
|6.||Azhdarinia, Ali: 1 article (05/2012)|
|7.||Hazen, Amy: 1 article (05/2012)|
|8.||Haviland, David L: 1 article (05/2012)|
|9.||Rockey, William M: 1 article (07/2011)|
|10.||Giangrande, Paloma H: 1 article (07/2011)|
|1.||Prostatic Neoplasms (Prostate Cancer)
05/01/2012 - "Antibody specific for epithelial cell adhesion molecule was conjugated to DOTA-NHS-ester, labeled with IRDye 800CW and further labeled with (64)Cu or nonradioactive Cu prior to reacting with human prostate cancer cells for testing by the Lindmo or FC method, respectively. "
04/01/2005 - "Mass spectral analyses of labile DOTA-NHS and heterogeneity determination of DOTA or DM1 conjugated anti-PSMA antibody for prostate cancer therapy."
07/01/2011 - "Three commercially available bifunctional macrocyclic chelators (1,4,7,10-tetraazacyclododecane-1,4,7-triacetic acid mono N-hydroxysuccinimide [DOTA-NHS]; S-2-(4-isothiocyanatobenzyl)-1,4,7-triazacyclononane-1,4,7-triacetic acid [p-SCN-Bn-NOTA]; and p-SCN-Bn-3,6,9,15-tetraazabicyclo [9.3.1]pentadeca-1(15),11,13-triene-3,6,9-triacetic acid [p-SCN-Bn-PCTA]), as well as the polyamino-macrocyclic diAmSar (3,6,10,13,16,19-hexaazabicyclo[6.6.6] icosane-1,8-diamine) were conjugated to A10-3.2, a RNA aptamer which has been shown to bind specifically to a prostate cancer-specific cell-surface antigen (PSMA). "
|1.||RNA (Ribonucleic Acid)
|3.||Surface Antigens (Surface Antigen)
|6.||1,4,7- triazacyclononane- N,N',N''- triacetic acid (NOTA)